These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1108 related articles for article (PubMed ID: 24259638)

  • 41. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment.
    Benkert D; Krause KH; Wasem J; Aidelsburger P
    GMS Health Technol Assess; 2010 Sep; 6():Doc13. PubMed ID: 21289886
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New drugs for the treatment of attention-deficit/hyperactivity disorder.
    Pataki CS; Feinberg DT; McGough JJ
    Expert Opin Emerg Drugs; 2004 Nov; 9(2):293-302. PubMed ID: 15571486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder.
    Caballero J; Nahata MC
    Clin Ther; 2003 Dec; 25(12):3065-83. PubMed ID: 14749146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amphetamine-induced chorea in attention deficit-hyperactivity disorder.
    Morgan JC; Winter WC; Wooten GF
    Mov Disord; 2004 Jul; 19(7):840-842. PubMed ID: 15254949
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.
    Spiller HA; Hays HL; Aleguas A
    CNS Drugs; 2013 Jul; 27(7):531-43. PubMed ID: 23757186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter?
    Hodgkins P; Shaw M; McCarthy S; Sallee FR
    CNS Drugs; 2012 Mar; 26(3):245-68. PubMed ID: 22329564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
    Sallee F; Connor DF; Newcorn JH
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature.
    Joshi G; Wilens T; Firmin ES; Hoskova B; Biederman J
    J Psychopharmacol; 2021 Mar; 35(3):203-210. PubMed ID: 33349107
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Should we keep on? Looking into pharmacogenomics of ADHD in adulthood from a different perspective.
    Rovaris DL; Mota NR; da Silva BS; Girardi P; Victor MM; Grevet EH; Bau CH; Contini V
    Pharmacogenomics; 2014 Jul; 15(10):1365-81. PubMed ID: 25155937
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-stimulant medications in the treatment of ADHD.
    Banaschewski T; Roessner V; Dittmann RW; Santosh PJ; Rothenberger A
    Eur Child Adolesc Psychiatry; 2004; 13 Suppl 1():I102-16. PubMed ID: 15322961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.
    Himpel S; Banaschewski T; Heise CA; Rothenberger A
    Expert Opin Drug Saf; 2005 Mar; 4(2):311-21. PubMed ID: 15794722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Attention-deficit hyperactivity disorder.
    Biederman J; Faraone SV
    Lancet; 2005 Jul 16-22; 366(9481):237-48. PubMed ID: 16023516
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attention-Deficit/Hyperactivity Disorder.
    Bokor G; Anderson PD
    J Pharm Pract; 2014 Aug; 27(4):336-49. PubMed ID: 25092688
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnosis and management of ADHD in children.
    Felt BT; Biermann B; Christner JG; Kochhar P; Harrison RV
    Am Fam Physician; 2014 Oct; 90(7):456-64. PubMed ID: 25369623
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alternative pharmacological strategies for adult ADHD treatment: a systematic review.
    Buoli M; Serati M; Cahn W
    Expert Rev Neurother; 2016; 16(2):131-44. PubMed ID: 26693882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.
    Schoretsanitis G; de Leon J; Eap CB; Kane JM; Paulzen M
    CNS Drugs; 2019 Dec; 33(12):1201-1222. PubMed ID: 31776871
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiovascular Effects of Drugs Used to Treat Attention-Deficit/Hyperactivity Disorder: Part 1: Epidemiology, Pharmacology, and Impact on Hemodynamics and Ventricular Repolarization.
    Fay TB; Alpert MA
    Cardiol Rev; 2019; 27(3):113-121. PubMed ID: 30365404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse Gestational Outcomes Associated With Attention-Deficit/Hyperactivity Disorder Medication Exposure During Pregnancy.
    Andrade C
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505179
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.